Brief: Immunicum AB Presents Updated Data From Phase Ii Mereca Trial Of Ilixadencel In Kidney Cancer

Mendus AB (publ)

07/02/2020 01:02

Feb 6 (Reuters) - Immunicum AB  IMMUN.ST :
    * REG-IMMUNICUM AB (PUBL) PRESENTS UPDATED DATA FROM PHASE
II
MERECA TRIAL OF ILIXADENCEL IN KIDNEY CANCER AT ASCO-SITC
CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM
    * IMMUNICUM -SURVIVAL AS OF DEC WAS 54% IN ILIXADENCEL
TREATMENT
GROUP COMPARED WITH 37% OF PATIENTS IN CONTROL GROUP TREATED
WITH SUNITINIB MONOTHERAPY
    * IMMUNICUM - DATA AS OF DEC 2019 DEMONSTRATES SEPARATION IN
KAPLAN-MEIER SURVIVAL CURVES IN FAVOR OF ILIXADENCEL TREATMENT
GROUP

Source text for Eikon:  ID:nGNE7RmBht 
Further company coverage:  IMMUN.ST 

 ((Reuters.Briefs@thomsonreuters.com;))